Departure Of Ariad Pharmaceuticals, Inc. Director Sparks Speculation That CEO Berger's Days Are Numbered

The departure of business adviser Robert Whelan from the board of directors at Ariad Pharmaceuticals last week is fueling speculation that CEO and co-founder Harvey Berger may soon be under pressure to step down from the struggling cancer biotech firm.

Whelan’s resignation from Ariad’s (Nasdaq: ARIA) 10-member board of directors effective Oct. 1 was revealed in a federal filing last week. He served on the board since 2010, and a replacement has not yet been named.

Help employers find you! Check out all the jobs and post your resume.